Inferent Focus for week ending 17 July 26: US Investment Banks, Netflix and United Health Group
The US Investment Banks, Netflix and UnitedHealth
Introduction
This week we’ve had a ramp up in Q2 earnings reports. With Inferent Analyst workflows being tested within the app development, we are analyzing hundreds of stocks agentically over the course of the earnings season producing quantitative earnings analysis, earnings call insight reports, earnings quality assessments, examinations of sentiment trends and inflections, risk reports and assessments of analyst forecast changes and stock price moves. During the development phase, many of these reports we lodge on our stock research page - but we do not email or even flag all these reports as the volume would overwhelm. We invite readers to subscribe and access our page often: Stock Research. Everything there is free and open to all.
Out of this body of work however, we expect a number of interesting situations to be identified. In this Focus Series across the earnings season, I will be flagging stocks that stand out from the agentic intelligence that Inferent Analyst workflows generate for both good and bad reasons - situations where management are calling out accelerating conditions as well as where we detect deterioration in trends that could affect future stock price performance.
The reports are intended to be informational but are not recommendations and are subject to the disclaimer contained at the end. We invite you to do two things:
Subscribe to inferential investor to receive these highlight reports; and
Pre-register for early access to Inferent Analyst on launch.
Whats Capturing Our Interest: Week Ended 17 July 2026
Out of the plethora of stocks that reported this week 3 situations stood out:.
Accelerating Conditions:
Historic results and growth from the US investment banks reflect an incredibly buoyant dealflow pipeline that is driving an historic earnings surge:
Far from showing late cycle fatigue, the largest financial institutions have delivered some of the strongest financial performances in modern banking history.
This reporting cycle was defined by record breaking investment banking and equities trading results, exceptionally stable credit metrics, and a notable shift in corporate strategy.
The overall message is that the US banking giants are capitalizing on a robust, AI driven macroeconomic backdrop while preparing for a more stabilized regulatory regime, establishing a highly resilient and structurally enhanced baseline for future growth.
With many investors chasing crowded AI trades, and even looking to second derivative cyclicals like CAT 0.00%↑ for exposure which have already seen their P/E ratios double, the US investment banks are an interesting consideration. They are benefiting from a massive wave of financing requirements for AI infrastructure and showing 30% profit growth, but have not re-rated in terms of valuation multiples to the same extent as other, technology exposed candidates.
See report at the bottom. Synthesized takeaways from a sector perspective plus individual stock reports across 6 large US commercial and banks.
Deteriorating Signals:
Netflix might still be growing but its trends may be challenging for the share price:
Netflix’s growth rebound could be faltering. The company missed consensus and set its guidance below analyst forecasts.
Growth decelerated sequentially for a third successive quarter and free cashflows declined. Revenue growth has declined from 16% pa to 11% pa FX neutral. Management maintain a consistent TAM message, however investors will focus on this slowdown until it is stabilized.
Management sentiment scores declined from a sequential comparison of the MD&A across their last 3 reports. The founder and chairman has announced his intention to not stand for re-election which introduces some governance uncertainty. On the back of the failure to acquire WB, this adds to the growth uncertainty.
The stock has already de-rated to 20x NTM EPS but if growth continues to slow we cant rule out further de-rating.
Refer report linked at the bottom.
UnitedHealth Group has rebounded strongly from its share price trough, however further performance may be impacted by deteriorating medical cost trends:
UNH has now raised its earnings guidance across three calls: FY2026 adjusted EPS guidance rose from “>$17.75” (Q4/FY25 call, 8.6% growth) to “>$18.25” (Q1’26) to “$19.50–$20.00” (Q2’26) — a cumulative increase of roughly 12–13% versus the initial post-restatement guide. This has already driven a large rebound in the share price.
However this was the first report where some new negative signals emerged.
Commercial medical cost trend were called out to be running “modestly above” the already-elevated 11% assumption, driven by an “ineffective” independent dispute resolution (IDR) process under the No Surprises Act and rising provider coding intensity. Management now frames the return to historical Commercial Group margins (7%+) as delayed beyond 2027.
Sentiment in management prepared remarks rose from cautious/rebuilding of Q4 FY25 (9) to constructive in Q1’26 (14) but retraced in Q2’26 (13), as analysts increasingly probed the sustainability of the earnings baseline and the newly emerging commercial cost-trend problem.
This may have share price performance implications going forward as revenue growth slows while the risk of accelerating costs rises.
Links to the individual reports follow our introduction below to the Inferent system. We invite you to pre-register for early access on launch.
Imagine you have an investment team at your disposal agentically analyzing events as they occur across tens of thousands of global stocks and flagging insights to you. Inferent Analyst is being designed to interpret and analyze data and events automatically, as situations evolve, presenting you with the insights you need to discover ideas and make better investment decisions. Pre-register today as subscriber seats will be limited on launch.
US Investment Banks Report:
Netflix Q2 Analysis
United Health Group Analysis
Important Disclaimer: This analysis is subject to The Inferential Investor’s Disclaimer. It is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, an offer or solicitation, or a guarantee of future performance. The information is derived from sources believed to be reliable but no representation or warranty is made as to its accuracy or completeness. Any forward looking or scenario descriptions are not forecasts but explorations of the implications of a set of described conditions and are subject to risk and uncertainty. Past performance is not indicative of future results. Readers should consult their own advisers before making any investment decision. This analysis is generated based on a standardized workflow. It has been prepared without taking account of your objectives, financial situation, or needs and does not constitute a recommendation on any security mentioned. You should consider the appropriateness of this information before making any investment decisions. AI can make mistakes.